Меню
Идёт набор NCT05926219

C-Protein in Fatigue and Aging

Без фазы С лечением Aging Muscle Atrophy or Weakness Sarcopenia in Elderly Sarcopenia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Fatiguing Exercise.
Кому может быть актуально
Состояния в реестре: Aging, Muscle Atrophy or Weakness, Sarcopenia in Elderly, Sarcopenia. Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Skeletal Muscle Myosin Binding Protein C in Fatigue and Aging

Обзор

This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.

Подробное описание

Age-related muscle atrophy and contractile dysfunction have been well described at the cellular level, but the molecular mechanisms that contribute to this dysfunction are poorly understood. Improved understanding of these mechanisms is critically important for the improvement of physical rehabilitation in older adults at risk for mobility impairment and physical disability. Our studies will pursue pre-clinical evidence that post translational modification of specific proteins in skeletal muscle lead to an "aging phenotype" in skeletal muscle that may unlock new strategies for improving physical function in older adults with physical frailty.

Вмешательства

  • Поведенческое Fatiguing Exercise
    Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once establ

Первичные конечные точки

  • Phosphorylation of myosin binding protein c (MyBP-C) [Срок оценки: One week after the participant undergoes the biopsies.]
Вторичные конечные точки (4)
  • Muscle fiber Force [Срок оценки: Within three weeks of the intervention and biopsies.]
  • Muscle fiber Tension [Срок оценки: Within three weeks of the intervention and biopsies.]
  • Muscle fiber Velocity [Срок оценки: Within three weeks of the intervention and biopsies.]
  • Muscle fiber Power [Срок оценки: Within three weeks of the intervention and biopsies.]

Критерии участия

Критерии включения

  • Adults between the ages 18-35 or 65-80 years
  • Healthy by self-report
  • Willing to participate in all aspects of the study design including muscle biopsy, unilateral exercise, and physical activity monitoring
  • Fluent in English (due to lack of translation services, it is not practical to conduct the study using a language other than English).

Критерии исключения

  • Orthopaedic limitation (severe knee osteoarthritis, prior joint replacement, etc.).
  • Volunteer has dementia or related mental issues that potentially put the subject at risk as determined by prior diagnosis.
  • Volunteer has known untreated endocrine disease (hypo/hyper thyroidism, Addison's Disease or Cushing's syndrome, etc.)
  • Volunteer has untreated/poorly-controlled hypertension (stage 2, per American College of Cardiology \[>140/90 mmHg\]).
  • Volunteer has significant heart, liver, kidney or respiratory disease.
  • Volunteer has diabetes (insulin dependent or non-insulin dependent).
  • Volunteer has known coagulopathies.
  • Volunteer has taken anabolic steroids in the prior six months.
  • Volunteer has received treatment for cancer (other than effective Mohs Surgery for successful removal of basal cell or squamous cell carcinomas)
  • Unexpected weight loss >5kg is last 12 months
  • Volunteer is an active smoker or quit within the last year.
  • Volunteer has known current alcohol or drug use disorder (AUD; defined as binge drinking of >4 days in the last month. Binge drinking is >5 drinks for men and >4 drinks for women, per occasion). Or, if a volunteer reports drinking in excess of "low risk" per NIAAA (>7 drinks/week for men and >3 drinks/day for women and >14 drinks/week and >4 drinks/day).
  • Volunteer has a diagnosed neuromuscular disorder.
  • Volunteer has allergy to lidocaine.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Фундаментальное исследование

Центры проведения

США · 1 центр
  • University of Oregon — Eugene

Идентификаторы

NCT: NCT05926219 · 11262017.042 · R21AG077125-01

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗